

Appendix 1 - Vaccines Procured

Programme	Vaccine	Manufacturer	Cohort
2016/17	Trivalent Influenza Vaccine (egg-based)	Pfizer Sanofi Seqirus	All adults in eligible cohorts
	Quadrivalent Influenza Vaccine (egg-based)	GSK	Children contraindicated to LAIV
2017/18	Trivalent Influenza Vaccine (egg-based)	Pfizer Sanofi BGP	All adults in eligible cohorts
	Quadrivalent Influenza Vaccine (egg-based)	Sanofi	Children contraindicated to LAIV
2018/19	Adjuvanted Trivalent Vaccine	Seqirus	Over-65s
	Quadrivalent Influenza Vaccine (egg-based)	Sanofi	Eligible adults aged 18-64
		BGP	Children contraindicated to LAIV
2019/20	Adjuvanted Trivalent Vaccine	Seqirus	Over-65s
	Cell-based Quadrivalent Vaccine	Seqirus	Eligible adults aged 18-64
	Quadrivalent Influenza Vaccine (egg-based)	Sanofi	Children contraindicated to LAIV
2020/21	Adjuvanted Trivalent Vaccine	Seqirus	Over-65s
	Cell-based Quadrivalent Vaccine	Seqirus	Eligible adults aged 18-64
	Quadrivalent Influenza Vaccine (egg-based)	GSK*	Eligible adults aged 18-64
	Quadrivalent Influenza Vaccine (egg-based)	Sanofi	Children contraindicated to LAIV
2021/22	Adjuvanted Quadrivalent Vaccine	Seqirus	Over-65s
	Cell-based Quadrivalent Vaccine	Seqirus	Eligible adults aged 18-64
	Recombinant Quadrivalent Vaccine	Sanofi	Eligible adults aged 18-64
	Quadrivalent Influenza Vaccine (egg-based)	Sanofi	Children contraindicated to LAIV
2022/23	Adjuvanted Quadrivalent Vaccine	Seqirus	Over-65s
	Cell-based Quadrivalent Vaccine	Seqirus	Eligible adults aged 18-64
	Quadrivalent Influenza Vaccine (egg-based)	Sanofi	Children contraindicated to LAIV
2023/24	Adjuvanted Quadrivalent Vaccine	Seqirus	Over-65s
	Cell-based Quadrivalent Vaccine	Seqirus	Eligible adults aged 18-64
Children contraindicated to LAIV			